✉ Email this page to a colleague
« Back to Dashboard
Cediranib is an investigational drug.
There have been 102 clinical trials for Cediranib. The most recent clinical trial was a Phase 3 trial, which was initiated on November 6th 2008.
The most common disease conditions in clinical trials are Carcinoma, Ovarian Neoplasms, and Lung Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), AstraZeneca, and NRG Oncology.
Recent Clinical Trials for Cediranib
|Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents||NRG Oncology||Phase 2|
|Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents||National Cancer Institute (NCI)||Phase 2|
|Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer||National Cancer Institute (NCI)||Phase 2|